Aptamer Group Plc (GB:APTA)
LSE:APTA
Want to see GB:APTA full AI Analyst Report?
APTA Stock Chart & Stats
0.80 p
-0.01 p(-2.86%)
At close: 4:00 PM EST
0.80 p
-0.01 p(-2.86%)
Day’s Range― - ―
52-Week Range0.30 p - 1.57 p
Previous CloseN/A
Volume3.91M
Average Volume (3M)15.29M
Market Cap
£20.73M
Enterprise Value16.37M
Total Cash (Recent Filing)£1.53M
Total Debt (Recent Filing)£333.00K
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Oct 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding3,455,144,000
10 Day Avg. Volume14,821,052
30 Day Avg. Volume15,285,032
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.32
Price to Sales (P/S)6.11
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Aptamer Platform & Diversified End-marketsAptamer Group's platform-focus across diagnostics, therapeutics and bioprocessing is a durable strategic asset. Platform technologies enable repeatable discovery services, licensing and product sales across multiple end markets, reducing single-market dependency and supporting long-term revenue channels if adoption grows.
Improved Leverage ManagementAn improved debt-to-equity profile materially raises financial flexibility over the medium term. Lower leverage reduces refinancing and interest risks, giving the company more runway to fund R&D, partnerships or commercialization efforts without immediate solvency pressure.
Lean Operating FootprintA small, focused team helps limit fixed costs and can extend cash runway while the company refines its products and goes-to-market. For a technology-driven biotech firm, a lean org structure supports agility in R&D and partnership negotiations and reduces burn compared with larger peers.
Bears Say
Severe Revenue CollapseA near-total revenue collapse is a fundamental red flag for long-term viability. It signals lost customer demand, failed product commercialization or contract timing issues, sharply limiting internal funding for R&D and commercialization and increasing reliance on external financing or partnerships.
Persistent Losses And Negative MarginsSustained negative gross, EBIT and net margins indicate structural profitability issues rather than temporary variability. Without a clear path to margin recovery, the firm will struggle to reinvest, attract strategic partners on favorable terms, or reach self-sustaining operations over the medium term.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows create persistent cash burn, forcing dependence on capital raises or credit. This constrains strategic options, risks dilution for existing shareholders, and can limit the company's ability to fund trials, scale manufacturing or commercial launches over several quarters.
Aptamer Group Plc News
APTA FAQ
What was Aptamer Group Plc’s price range in the past 12 months?
Aptamer Group Plc lowest share price was 0.30 p and its highest was 1.57 p in the past 12 months.
What is Aptamer Group Plc’s market cap?
Aptamer Group Plc’s market cap is £20.73M.
When is Aptamer Group Plc’s upcoming earnings report date?
Aptamer Group Plc’s upcoming earnings report date is Oct 20, 2026 which is in 164 days.
How were Aptamer Group Plc’s earnings last quarter?
Aptamer Group Plc released its earnings results on Mar 25, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Aptamer Group Plc overvalued?
According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued.
Does Aptamer Group Plc pay dividends?
Aptamer Group Plc does not currently pay dividends.
What is Aptamer Group Plc’s EPS estimate?
Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptamer Group Plc have?
Aptamer Group Plc has 3,455,144,000 shares outstanding.
What happened to Aptamer Group Plc’s price movement after its last earnings report?
Aptamer Group Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Aptamer Group Plc?
Currently, no hedge funds are holding shares in GB:APTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptamer Group Plc
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom and internationally. The company's binders engineered to address issues which founds with molecules, such as antibodies; and offers solutions to bioprocessing, diagnostic, and pharmaceutical scientists. It serves pharma companies, diagnostic development companies, and research institutes. The company was incorporated in 2014 and is based in York, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Arecor Therapeutics PLC
―
Options Prices
Currently, No data available
---